Aveanna Healthcare Reports Strong Q1 Results, Raises Full-Year 2026 Revenue and EBITDA Guidance
AVAH sits 86% above its 52-week low of $3.73 on elevated volume (2.9× avg).
Summary
Aveanna Healthcare reported strong first-quarter financial results, with significant increases in revenue and profitability, and subsequently raised its full-year 2026 guidance.
Key Events · Earnings and Guidance · AVAH
-
Strong Q1 2026 Financial Performance
Revenue increased by 15.9% to $647.9 million, net income surged to $41.7 million from $5.2 million in the prior year, and Adjusted EBITDA grew by 25.2% to $84.4 million.
-
Raised Full-Year 2026 Guidance
The company increased its full-year 2026 revenue guidance to between $2.56 and $2.58 billion (from $2.54 - $2.56 billion) and Adjusted EBITDA guidance to between $328 and $332 million (from $318 - $322 million).
-
Positive Organic Growth
CEO Jeff Shaner highlighted the strength and resiliency of the business model, noting that the revised guidance reflects positive momentum and excludes the pending Family First Homecare acquisition.
Analysis · AVAH · Industrial Applications And Services
Aveanna Healthcare delivered a strong first quarter, significantly increasing revenue, net income, and Adjusted EBITDA year-over-year. The company also raised its full-year 2026 guidance for both revenue and Adjusted EBITDA, signaling positive momentum and confidence in its business model. This strong performance, which excludes the pending Family First Homecare acquisition, indicates robust organic growth and improved profitability.
At the time of this filing, AVAH was trading at $6.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $3.73 to $10.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.